Drug recall · June 2, 2021
Belsomra recall
Why: CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Belsomra (suvorexant) tablets 10 mg Each tablet contains 10 mg suvorexant. This package contains 30 Tablets in 3 Blister Cards. Each Blister Card contains 10 Tablets Rx only NDC 00006-0033-30 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Whitehouse Station, NJ 08889, USA
- Lots / codes
1791139
- Quantity
- 119 cartons
- Company
- Cardinal Health Inc., Dublin, OH
- Distribution
- FL, GA, SC
- Initiated
- March 15, 2021 · Voluntary: Firm initiated
- Classified
- May 24, 2021
- Reported
- June 2, 2021
- Ended
- June 17, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Belsomra
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.